Orserdu Den europeiske union - norsk - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Viread 245 mg Norge - norsk - Statens legemiddelverk

viread 245 mg

2care4 - tenofovirdisoproksilfumarat - tablett, filmdrasjert - 245 mg

Nicotinell 21 mg/24 timer Norge - norsk - Statens legemiddelverk

nicotinell 21 mg/24 timer

haleon denmark aps - nikotin - depotplaster - 21 mg/24 timer

Nicotinell 7 mg/24 timer Norge - norsk - Statens legemiddelverk

nicotinell 7 mg/24 timer

haleon denmark aps - nikotin - depotplaster - 7 mg/24 timer

Nicotinell 14 mg/24 timer Norge - norsk - Statens legemiddelverk

nicotinell 14 mg/24 timer

haleon denmark aps - nikotin - depotplaster - 14 mg/24 timer

Scopoderm 1 mg/72 timer Norge - norsk - Statens legemiddelverk

scopoderm 1 mg/72 timer

baxter medical ab - skopolamin - depotplaster - 1 mg/72 timer

Voltarol 12.5 mg Norge - norsk - Statens legemiddelverk

voltarol 12.5 mg

glaxosmithkline consumer healthcare a/s (1) - diklofenakkalium - kapsel, myk - 12.5 mg

Voltarol 25 mg Norge - norsk - Statens legemiddelverk

voltarol 25 mg

glaxosmithkline consumer aps - diklofenakkalium - kapsel, myk - 25 mg

Voltarol 25 mg Norge - norsk - Statens legemiddelverk

voltarol 25 mg

glaxosmithkline consumer aps - diklofenakkalium - tablett, drasjert - 25 mg

Voltarol 12.5 mg Norge - norsk - Statens legemiddelverk

voltarol 12.5 mg

glaxosmithkline consumer aps - diklofenakkalium - tablett, filmdrasjert - 12.5 mg